Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

Cited by (999)

Items 101–200 of 999

1. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment
   Diego Omar Croci, Mariano F. Zacarías Fluck, María José Rico, Pablo Matar, Gabriel A. Rabinovich, Olga Graciela Scharovsky · 2007 · Cancer Immunology Immunotherapy
2. Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy
   Seema Gupta, Amrita Roy, Bilikere Srinivasa Rao Dwarakanath · 2017 · Frontiers in Oncology
3. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma
   Tomoko Inaba, Kazuhiko Ino, Hiroaki Kajiyama, Eiko Yamamoto, Kiyosumi Shibata, Akihiro Nawa, Tetsuro Nagasaka, Hidetoshi Akimoto, Osamu Takikawa, Fumitaka Kikkawa · 2009 · Gynecologic Oncology
4. The BAR Domain Proteins: Molding Membranes in Fission, Fusion, and Phagy
   Gang Ren, P. Vajjhala, Janet S. Lee, Barbara Winsor, A. Munn · 2006 · Microbiology and Molecular Biology Reviews
5. Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form
   Micah T. Nelp, Patrick A. Kates, John T. Hunt, John A. Newitt, Aaron Balog, Derrick Maley, Xiao Bing Zhu, Lynn M. Abell, Alban J. Allentoff, R. M. Borzilleri et al. · 2018 · Proceedings of the National Academy of Sciences
6. Activity and specificity of necrostatin-1, small-molecule inhibitor of RIP1 kinase
   Alexei Degterev, Jenny L. Maki, Junying Yuan · 2012 · Cell Death and Differentiation
7. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: Focus on macrophage polarization of THP-1 cells
   Xianfeng Wang, Hongsheng Wang, Hao Wang, Fan Zhang, Ke-Fang Wang, Qiang Guo, Ge Zhang, Shaohui Cai, Jun Du · 2014 · Cellular Immunology
8. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
   Seyed Esmaeil Ahmadi, Samira Rahimi, Bahman Zarandi, Rouzbeh Chegeni, Majid Safa · 2021 · Journal of Hematology & Oncology
9. Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
   Ute F. Röhrig, Somi Reddy Majjigapu, Pierre Vogel, Vincent Zoete, Olivier Alain Michielin · 2015 · Journal of Medicinal Chemistry
10. IDO Expression in Cancer: Different Compartment, Different Functionality?
    Annabel Meireson, Michaël Devos, Liève Brochez · 2020 · Frontiers in Immunology
11. Molecular insights into substrate recognition and catalysis by tryptophan 2,3-dioxygenase
    F. Forouhar, J. L. Ross Anderson, Christopher G. Mowat, Sergey M. Vorobiev, Arif Hussain, Mariam Abashidze, Chiara Bruckmann, Sarah J. Thackray, J. Seetharaman, Todd Tucker et al. · 2006 · Proceedings of the National Academy of Sciences
12. Metabolite interactions between host and microbiota during health and disease: Which feeds the other?
    Yan Zhang, Rui Chen, DuoDuo Zhang, Shuang Qi, Yan Liu · 2023 · Biomedicine & Pharmacotherapy
13. Biologically active quinoline and quinazoline alkaloids part II
    Xiaofei Shang, Susan Lynne Morris-Natschke, Guan‐Zhou Yang, Ying‐Qian Liu, Xiao Guo, Xiaoshan Xu, Masuo Goto, Juncai Li, Jiyu Zhang, Kuo‐Hsiung Lee · 2018 · Medicinal Research Reviews
14. Amino acid catabolism: a pivotal regulator of innate and adaptive immunity
    Tracy L. McGaha, Lei Huang, Henrique de Paula Lemos, Richard A. Metz, Mario R. Mautino, George C. Prendergast, Andrew L. Mellor · 2012 · Immunological Reviews
15. Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive ‘Cold’ Tumors ‘Hot’
    George C. Prendergast, Arpita Mondal, Souvik Dey, Lisa D. Laury‐Kleintop, Alexander J. Muller · 2017 · Trends in cancer
16. Bridging integrator 1 (BIN1): form, function, and Alzheimer's disease
    Meng‐Shan Tan, Jin‐Tai Yu, Lan Tan · 2013 · Trends in Molecular Medicine
17. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation
    Richard A. Metz, Courtney Smith, James B. DuHadaway, Phillip Chandler, Babak Baban, Lauren M.F. Merlo, Elizabeth Pigott, Martin P. Keough, Sonja Rust, Andrew L. Mellor et al. · 2014 · International Immunology
18. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy
    Yichao Chen, Rui Xia, Yixian Huang, Wenchen Zhao, Jiang Li, Xiaolan Zhang, Pengcheng Wang, Raman Venkataramanan, Jie Fan, Wen Xie et al. · 2016 · Nature Communications
19. Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (LLC) Tumor-Bearing Mice
    Shuangshuang Yang, Xishuai Li, Fangfang Hu, Yinlong Li, Yunyun Yang, Junkai Yan, Chunxiang Kuang, Qing Yang · 2013 · Journal of Medicinal Chemistry
20. Trial watch: IDO inhibitors in cancer therapy
    Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer, Erika Vacchelli · 2020 · OncoImmunology
21. Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
    Takefumi Komiya, Chao Hui Huang · 2018 · Frontiers in Oncology
22. Toward the identification of a tolerogenic signature in IDO-competent dendritic cells
    Ciriana Orabona, Paolo Puccetti, Carmine Vacca, Silvio Bicciato, Alessandra Luchini, Francesca Fallarino, Roberta Bianchi, Enrico Velardi, Katia Perruccio, Andrea Velardi et al. · 2005 · Blood
23. Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway
    Dechun Liu, Binlong Chen, Yulin Mo, Zenghui Wang, Tong Qi, Qiang Zhang, Yiguang Wang · 2019 · Nano Letters
24. Indoleamine 2,3-Dioxygenase
    Hatem Hussein Soliman, Melanie Mediavilla-Varela, Scott Joseph Antonia · 2010 · The Cancer Journal
25. Tryptophan 2,3-Dioxygenase (TDO) Inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators
    Eduard Dolušić, Pierre Larrieu, Laurence Moineaux, Vincent Stroobant, Luc Pilotte, Didier Colau, Lionel Pochet, Benoit J. Van den Eynde, Bernard Masereel, Johan Wouters et al. · 2011 · Journal of Medicinal Chemistry
26. Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy
    Zhiren Wang, Nicholas Little, Jiawei Chen, Kevin Tyler Lambesis, Kimberly Thi Le, Weiguo Han, Aaron James Scott, Jianqin Lu · 2021 · Nature Nanotechnology
27. Indoleamine 2,3‐dioxygenase: From catalyst to signaling function
    F. Fallarino, U. Grohmann, P. Puccetti · 2012 · European Journal of Immunology
28. Structure−Activity Study of Brassinin Derivatives as Indoleamine 2,3-Dioxygenase Inhibitors
    Paul M. Gaspari, Tinku Banerjee, William P. Malachowski, Alexander J. Muller, George C. Prendergast, James B. DuHadaway, Shauna M. Bennett, Ashley M. Donovan · 2005 · Journal of Medicinal Chemistry
29. Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells
    Mario Ricciardi, Marco Zanotto, Giorgio Malpeli, G. Bassi, Omar Perbellini, Marco Chilosi, Francesco Bifari, Mauro Krampera · 2015 · British Journal of Cancer
30. Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy
    Alisha Holtzhausen, Fei Linda Zhao, Kathy S. Evans, Masahito Tsutsui, Ciriana Orabona, Douglas S. Tyler, Brent Allen Hanks · 2015 · Cancer Immunology Research
31. Kynurenine Pathway Enzymes in Dendritic Cells Initiate Tolerogenesis in the Absence of Functional IDO
    Maria Laura Belladonna, Ursula Grohmann, Paolo Guidetti, Claudia Volpi, Roberta Bianchi, Maria C. Fioretti, Robert M. Schwarcz, Francesca Fallarino, Paolo Puccetti · 2006 · The Journal of Immunology
32. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation
    David H. Munn · 2006 · Current Opinion in Immunology
33. The Mannose Receptor Mediates the Uptake of Diverse Native Allergens by Dendritic Cells and Determines Allergen-Induced T Cell Polarization through Modulation of IDO Activity
    Pierre‐Joseph Royer, Mohamed Mahrous Emara, Chaoxing Yang, Abeer Al-Ghouleh, Patrick J. Tighe, Nick Jones, Herb F. Sewell, Farouk Shakib, Luisa Martínez‐Pomares, Amir M. Ghaemmaghami · 2010 · The Journal of Immunology
34. The Endogenous Tryptophan Metabolite and NAD+ Precursor Quinolinic Acid Confers Resistance of Gliomas to Oxidative Stress
    Felix Sahm, Iris Oezen, Christiane A. Opitz, Bernhard Radlwimmer, Andreas von Deimling, Tilman Ahrendt, Seray Adams, Helge B. Bode, Gilles J. Guillemin, Wolfgang Wick et al. · 2013 · Cancer Research
35. Liposome-Based Drug Delivery Systems in Cancer Immunotherapy
    Zili Gu, Candido G. Da Silva, Koen van der Maaden, FERRY A. OSSENDORP, Luis Javier Cruz · 2020 · Pharmaceutics
36. Interferon-γ–triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells
    Jürgens, Birgit, Hainz, Ursula, Fuchs, Dietmar, Felzmann, Thomas, Heitger, Andreas · 2009 · Blood
37. Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?
    Van den Eynde, Benoit J., van Baren, Nicolas, Baurain, Jean-François · 2020 · Annual Review of Cancer Biology
38. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
    Soliman, Hatem H., Jackson, Erica, Neuger, Tony, Dees, E. Claire, Harvey, R. Donald, Han, Hyo, Ismail-Khan, Roohi, Minton, Susan, Vahanian, Nicholas N., Link, Charles et al. · 2014 · Oncotarget
39. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase
    Tinku Banerjee, James B. DuHadaway, Paul M. Gaspari, Erika Sutanto‐Ward, David H. Munn, Andrew L. Mellor, William P. Malachowski, George C. Prendergast, Alexander J. Muller · 2007 · Oncogene
40. Paclitaxel and immune system
    Aqeel Javeed, Muhammad Ashraf, Amjad Riaz, Aamir Ghafoor, Sheryar Afzal, Muhammad Mahmood Mukhtar · 2009 · European Journal of Pharmaceutical Sciences
41. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery
    Javed Khan, F. Forouhar, Xiao Tao, Liang Tong · 2007 · Expert Opinion on Therapeutic Targets
42. Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition
    Ute F. Röhrig, Somi Reddy Majjigapu, Aurélien Grosdidier, Sylvian Bron, Vincent Stroobant, Luc Pilotte, Didier Colau, Pierre Vogel, Benoit J. Van den Eynde, Vincent Zoete et al. · 2012 · Journal of Medicinal Chemistry
43. Expression of Indoleamine 2,3-Dioxygenase in Tumor Endothelial Cells Correlates with Long-term Survival of Patients with Renal Cell Carcinoma
    Rainer Riesenberg, Christoph Weiler, Oliver Spring, Martin Eder, Alexander Büchner, Tanja Popp, Mirna Castro, Robert Kammerer, Osamu Takikawa, Rudolf Alexander Hatz et al. · 2007 · Clinical Cancer Research
44. Indoleamine 2,3-Dioxygenase Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors
    Sanjeev Kumar, William P. Malachowski, James B. DuHadaway, Judith M. LaLonde, Patrick J. Carroll, Daniel Jaller, Richard A. Metz, George C. Prendergast, Alexander J. Muller · 2008 · Journal of Medicinal Chemistry
45. Next generation transcriptomics and genomics elucidate biological complexity of microglia in health and disease
    Wes, Paul D., Holtman, Inge R., Boddeke, Erik W.G.M., Möller, Thomas, Eggen, Bart J.L. · 2016 · Glia
46. Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites
    Powell Perng, Michael K. Lim · 2015 · Frontiers in Oncology
47. Identification of α-Enolase as an Autoantigen in Lung Cancer: Its Overexpression Is Associated with Clinical Outcomes
    Gee‐Chen Chang, Ko‐Jiunn Liu, Chia‐Ling Hsieh, Tsai-Shu Hu, Suparat Charoenfuprasert, Hsiung-Kun Liu, K T Luh, Li‐Han Hsu, Chew-Wen Wu, Chou‐Chik Ting et al. · 2006 · Clinical Cancer Research
48. Polyamine-Blocking Therapy Reverses Immunosuppression in the Tumor Microenvironment
    Candace S. Hayes, Allyson C. Shicora, Martin P. Keough, Adam Eugene Snook, Mark R. Burns, Susan K. Gilmour · 2013 · Cancer Immunology Research
49. Expression of indoleamine 2, 3‐dioxygenase and the recruitment of Foxp3‐expressing regulatory T cells in the development and progression of uterine cervical cancer
    Takafumi Nakamura, Tomoko Shima, Ai Saeki, 隆雄 日高, Akitoshi Nakashima, Osamu Takikawa, Shigeru Saito · 2007 · Cancer Science
50. Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease models
    Peter Vandenabeele, Sasker Grootjans, Nico Callewaert, Nozomi Takahashi · 2012 · Cell Death and Differentiation
51. A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy
    Samuel G. Awuah, Yao‐Rong Zheng, Peter M. Bruno, Michael T. Hemann, Stephen J. Lippard · 2015 · Journal of the American Chemical Society
52. Tryptophan metabolism: entering the field of aging and age-related pathologies
    Annemieke T. van der Goot, Ellen A. A. Nollen · 2013 · Trends in Molecular Medicine
53. Necroptosis, in vivo detection in experimental disease models
    Sandrine Jouan-Lanhouet, Franck B. Riquet, Linde Duprez, Tom Vanden Berghe, Nozomi Takahashi, Peter Vandenabeele · 2014 · Seminars in Cell and Developmental Biology
54. Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors
    Ute F. Röhrig, Loay Awad, Aurélien Grosdidier, Pierre Larrieu, Vincent Stroobant, Didier Colau, Vincenzo Cerundolo, Andrew J.G. Simpson, Pierre Vogel, Benoit J. Van den Eynde et al. · 2010 · Journal of Medicinal Chemistry
55. IDO1: An important immunotherapy target in cancer treatment
    Fangxuan Li, Rupeng Zhang, Shixia Li, Juntian Liu · 2017 · International Immunopharmacology
56. Activated CD69+ T Cells Foster Immune Privilege by Regulating IDO Expression in Tumor-Associated Macrophages
    Qiyi Zhao, Dong‐Ming Kuang, Yan Wu, Christos Xiao, Xuefeng Li, Tuan-Jie Li, Limin Zheng · 2011 · The Journal of Immunology
57. Inflammation and cancer: Breast cancer as a prototype
    Alberto Mantovani, Federica Marchesi, Chiara Porta, Antonio Sica, Paola Allavena · 2007 · The Breast
58. Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy
    Gaia Giannone, Eleonora Ghisoni, Sofia Genta, Giulia Scotto, Valentina Tuninetti, Margherita Turinetto, Giorgio Valabrega · 2020 · International Journal of Molecular Sciences
59. Differences in Gastric Carcinoma Microenvironment Stratify According to EBV Infection Intensity: Implications for Possible Immune Adjuvant Therapy
    Michael J. Strong, Guorong Xu, Joseph Coco, Carl Baribault, Dass S. Vinay, Michelle R. Lacey, Amy L. Strong, Teresa A. Lehman, Michael B. Seddon, Zhen Nan Lin et al. · 2013 · PLoS Pathogens
60. CXCR3+ T Regulatory Cells Selectively Accumulate in Human Ovarian Carcinomas to Limit Type I Immunity
    Nassima Redjimi, Caroline Raffin, Isabelle Raimbaud, Pascale Pignon, Junko Matsuzaki, Kunle O. Odunsi, Danila Valmori, Maha Ayyoub · 2012 · Cancer Research
61. Improving cancer immunotherapy by targeting tumor-induced immune suppression
    Trina J. Stewart, Mark John Smyth · 2011 · Cancer and Metastasis Reviews
62. Characterization of GSK′963: a structurally distinct, potent and selective inhibitor of RIP1 kinase
    SB Berger, Philip A. Harris, Rakesh Nagilla, Viera Kasparcova, S Hoffman, Brandon Swift, Lauren C. Dare, Michelle C. Schaeffer, Carol A. Capriotti, Michael T. Ouellette et al. · 2015 · Cell Death Discovery
63. Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy
    Shuai Wen, Guan Wang, Yiwen Zhang, Faqian Bu, Sicheng Zhang, Duane D. Miller, Wěi Li, Liang Ouyang, Yuxi Wang · 2021 · Journal of Medicinal Chemistry
64. Structure Based Development of Phenylimidazole-Derived Inhibitors of Indoleamine 2,3-Dioxygenase
    Sanjeev Kumar, Daniel Jaller, Bhumika Patel, Judith M. LaLonde, James B. DuHadaway, William P. Malachowski, George C. Prendergast, Alexander J. Muller · 2008 · Journal of Medicinal Chemistry
65. Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer
    Feng Qian, Jeannine Villella, Paul K. Wallace, Paulette Y. Mhawech-Fauceglia, Joseph Dennis Tario, Chris Andrews, Junko Matsuzaki, Danila Valmori, Maha Ayyoub, Peter Jonathan Frederick et al. · 2009 · Cancer Research
66. Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer
    Liesbeth Ferdinande, Christine Decaestecker, Laurine Verset, Anne Mathieu, Xavier Moles Lopez, A-M Negulescu, Tom Van Maerken, Isabelle J. Salmon, Claude A Cuvelier, Pieter Demetter · 2011 · British Journal of Cancer
67. Rational design of a minimalist nanoplatform to maximize immunotherapeutic efficacy: Four birds with one stone
    Shiyao Zhou, Qi Shang, Ningning Wang, Qian Li, Aixin Song, Yuxia Luan · 2020 · Journal of Controlled Release
68. Indoleamine 2,3 dioxygenase and regulation of T cell immunity
    Andrew L. Mellor · 2005 · Biochemical and Biophysical Research Communications
69. Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer
    Alexander J. Muller, George C. Prendergast · 2007 · Current Cancer Drug Targets
70. A phase I study of indoximod in patients with advanced malignancies
    Hatem Hussein Soliman, Susan E. Minton, Hyo Sook Han, Roohi R. Ismail-Khan, Anthony M. Neuger, Fatema Abbas Khambati, David R. Noyes, Richard M. Lush, Alberto Chiappori, John D. Roberts et al. · 2016 · Oncotarget
71. Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality
    Lisa K. Jasperson, Christoph Marcus Bucher, Angela Panoskaltsis‐Mortari, Patricia A. Taylor, Andrew L. Mellor, David H. Munn, Bruce R. Blazar · 2007 · Blood
72. The kynurenine pathway and inflammation in amyotrophic lateral sclerosis
    Chen, Yiquan, Stankovic, Roger, Cullen, Karen M., Meininger, Vincent, Garner, Brett, Coggan, Sarah, Grant, Ross, Brew, Bruce J., Guillemin, Gilles J. · 2010 · Neurotoxicity Research
73. The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
    Christiane A. Opitz, Ulrike M. Litzenburger, Uta Opitz, Felix Sahm, Katharina Ochs, Christian Lutz, Wolfgang Wick, Michael Platten · 2011 · PLoS ONE
74. Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase
    Kittipong Maneechotesuwan, Wuttichai Ekjiratrakul, Kanda Kasetsinsombat, Adisak Wongkajornsilp, Peter John Barnes · 2010 · Journal of Allergy and Clinical Immunology
75. Why tumours eat tryptophan
    George C. Prendergast · 2011 · Nature
76. Evidence for a ferryl intermediate in a heme-based dioxygenase
    Ariel Lewis-Ballester, Dipanwita Batabyal, Tsuyoshi Egawa, Changyuan Lu, Yu Hong Lin, Marcelo Adrian Marti, Luciana Capece, Dario Ariel Estrin, Syun‐Ru Yeh · 2009 · Proceedings of the National Academy of Sciences
77. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
    Minghui Li, Aaron R. Bolduc, Md Nasrul Hoda, Denise N. Gamble, Sarah-Bianca Dolisca, Anna Bolduc, Kelly Hoang, Claire Ashley, David C. McCall, Amyn M. Rojiani et al. · 2014 · Journal for ImmunoTherapy of Cancer
78. IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS‐treated dendritic cells
    Marcelo Hill, Séverine Tanguy‐Royer, Pierre‐Joseph Royer, Christine Chauveau, Kashif Asghar, Laurent Tesson, Frédéric Lavainne, Séverine Remy, Régis Brion, François‐Xavier Hubert et al. · 2007 · European Journal of Immunology
79. l-Kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species
    Hyunkeun Song, Hyunjin Park, Yeong-Seok Kim, Kwang Dong Kim, Hyun-Kyung Lee, Dae-Ho Cho, Jae-Wook Yang, Dae Young Hur · 2011 · International Immunopharmacology
80. Immune-mediated mechanisms influencing the efficacy of anticancer therapies
    Seth B. Coffelt, Karin E. de Visser · 2015 · Trends in Immunology
81. Understanding the role of the kynurenine pathway in human breast cancer immunobiology
    Benjamin Heng, Chai K. Lim, David B. Lovejoy, Alban Bessede, Laurence Gluch, Gilles J. Guillemin · 2015 · Oncotarget
82. Impact of Metabolism in on T-Cell Differentiation and Function and Cross Talk with Tumor Microenvironment
    Soumaya Kouidhi, Amel Benammar Elgaaïed, Salem Chouaı̈b · 2017 · Frontiers in Immunology
83. Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms
    Tiana Kordbacheh, Jamie Honeychurch, Fiona Helen Blackhall, Corinne Faivre Finn, Tim Illidge · 2017 · Annals of Oncology
84. Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy
    Steven F. Gameiro, Farhad Ghasemi, John W. Barrett, James D. Koropatnick, Anthony Charles Nichols, Joe S. Mymryk, Saman Maleki Vareki · 2018 · OncoImmunology
85. Dual biological effects of the cytokines interleukin-10 and interferon-γ
    Wilke, Cailin Moira, Wei, Shuang, Wang, Lin, Kryczek, Ilona, Kao, John, Zou, Weiping · 2011 · Cancer Immunology Immunotherapy
86. Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway
    Amy B. Dounay, Jamison B. Tuttle, Patrick R. Verhoest · 2015 · Journal of Medicinal Chemistry
87. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer
    Fangxuan Li, Yang Zhao, Lijuan Wei, Shixia Li, Juntian Liu · 2018 · Cancer Biology & Therapy
88. Blocking IDO activity to enhance anti-tumor immunity
    David H. Munn · 2012 · Frontiers in Bioscience-Elite
89. Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression
    Jing-Yi Chen, Chien‐Feng Li, Cheng-Chin Kuo, Kelvin K. Tsai, Ming‐Feng Hou, Wen-Chun Hung · 2014 · Breast Cancer Research
90. Tumor associated regulatory dendritic cells
    Yang Ma, Galina V. Shurin, Dmitriy W. Gutkin, Michael R. Shurin · 2012 · Seminars in Cancer Biology
91. The Kynurenine Pathway of Tryptophan Catabolism, CD4+ T-Cell Recovery, and Mortality Among HIV-Infected Ugandans Initiating Antiretroviral Therapy
    Helen Byakwaga, Yap Boum, Ying Huang, Conrad K. Muzoora, Annet Kembabazi, Sheri D. Weiser, J. Bennett, H. Cao, Jessica Elizabeth Haberer, Steven G. Deeks et al. · 2014 · The Journal of Infectious Diseases
92. Activation of Host Wound Responses in Breast Cancer Microenvironment
    Melissa A. Troester, Myung Hee Lee, Matthew J. Carter, Cheng Fan, David W. Cowan, Erick Roman Perez, Jason R. Pirone, Charles M. Perou, D. Joseph Jerry, Sallie S. Schneider · 2009 · Clinical Cancer Research
93. iRGD Modified Chemo‐immunotherapeutic Nanoparticles for Enhanced Immunotherapy against Glioblastoma
    Jing Kuang, Wen Long Song, Jun Yin, Xuan Zeng, Song Hee Han, Yipeng Zhao, Jun Tao, Chuan‐Jun Liu, Xiaohua He, Xian‐Zheng Zhang · 2018 · Advanced Functional Materials
94. Understanding the Biology of Antigen Cross-Presentation for the Design of Vaccines Against Cancer
    Cynthia M. Fehres, Wendy W. J. Unger, Juan Jesús García-Vallejo, Yvette van Kooyk · 2014 · Frontiers in Immunology
95. Cyclooxygenase-2 Inhibitor Enhances the Efficacy of a Breast Cancer Vaccine: Role of IDO
    Gargi Dan Basu, Teresa L. Tinder, Judy Martina Bradley, Tony Tu, Christine L. Hattrup, Barbara A. Pockaj, Pinku Mukherjee · 2006 · The Journal of Immunology
96. Mesenchymal Stem Cell Therapy Prevents Interstitial Fibrosis and Tubular Atrophy in a Rat Kidney Allograft Model
    Marcella Franquesa, Esther Herrero, Joan Torrás, Èlia Ripoll, Maria Flaquer, Montse Gomà, Núria Lloberas, Ignacio Anegón, Josep Maria Cruzado, Josep Maria Grinyo et al. · 2012 · Stem Cells and Development
97. Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment
    Juliane Günther, Jan Däbritz, Elisa Wirthgen · 2019 · Frontiers in Immunology
98. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease
    Antonio Macchiarulo, Emidio Camaioni, Roberto Nuti, Roberto Pellicciari · 2008 · Amino Acids
99. Food Fight: Role of Itaconate and Other Metabolites in Antimicrobial Defense
    Luan, Harding H., Medzhitov, Ruslan · 2016 · Cell Metabolism
100. Programmed necrosis in heart disease: Molecular mechanisms and clinical implications
     Hong Zhu, Aijun Sun · 2018 · Journal of Molecular and Cellular Cardiology